AccelBio

Founded in 2016, AccelBio operates as a specialized contract research and service provider in the biologics and cell therapy space. The company's core offering combines advanced cellular technologies—including proprietary cryopreservation and transgenic cell production—with high-throughput robotic automation to accelerate preclinical research for clients. While historically focused on research services and COVID-19 testing, AccelBio is expanding into cGMP/cGCP cell production for regenerative medicine and gene therapy, positioning itself as a potential CDMO partner for clinical-stage programs. Its business model is primarily service-based, catering to pharmaceutical, biotech, and academic institutions.

Integrated platform combining proprietary CRISPR cryopreservation for sensitive cells, high-throughput robotic cell-based assays, custom molecular biology (neuroscience/RNA biology), and preclinical in vivo model capabilities.

Competes with large CROs (e.g., Charles River, LabCorp) for research services and niche specialty cell/assay providers. In CDMO ambitions, will face established giants (Lonza, Catalent) and specialized cell therapy CDMOs. Differentiation hinges on proprietary cryopreservation and expertise in sensitive cell types.